Retinal Vein Occlusion Market Research Report Information By Type (Branch Retinal Artery Occlusion and Central Retinal Vein Occlusion), By Condition (Non-Ischemic and Ischemic), Diagnosis (Optical Coherence Tomography, Fundoscopic Examination and Fluorescein Angiography), Treatment (Antivascular Endothelial Growth Factor, Corticosteroid Drugs and Laser Retinal Photocoagulation), End User (Hospitals and Clinics and Research & Academics Centers) - Forecast till 2032

Global Retinal Vein Occlusion Market Overview

Retinal Vein Occlusion Market Size was valued at USD 15.30 Billion in 2023. The Global Retinal Vein Occlusion industry is projected to grow from USD 16.85 Billion in 2024 to USD 33.49 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.93% during the forecast period (2024 - 2032).

Market development is projected to increase the prevalence of diabetes, shift in lifestyle, and increase the occurrence of glaucoma, lymphoma, and multiple myeloma worldwide.

Biocon Biologics, a subsidiary of Biocon, officially announced on March 2023 that it has settled with Bayer and Regeneron Pharmaceuticals. Consequently, this agreement allows Biocon Biologics to introduce Yesafili®, a proposed biosimilar to EYLEA (aflibercept) Injection, into the Canadian market. According to the terms of the agreement, Biocon Biologics shall launch Yesafili no later than July 1st, 2025. In March 2023, Health Canada had granted tentative approval for Yesafili. Finally, under the terms of this deal, Biocon Biologics will be able to set up a launch date for Yesafili 2 mg New Drug Submission (NDS) vials and prefilled syringes by July 1st, 2025. The announcement was made subsequent to Health Canada granting provisional consent in March 2023 for Yesafili 2 mg vials.

Sandoz signed an agreement in January 2024 to acquire Coherus Biosciences’ Cimerli (ranibizumab-earn), a biosimilar ranibizumab, for a $170 million upfront cash payment upon purchase. This includes biologic licensed applications, product inventory, ophthalmology sales, field reimbursement expertise, and access to proprietary commercial software. It falls under the category of biologics that provide anti-VEGF therapy, which helps retina patients maintain or gain vision. It got the FDA’s approval in August last year (August 2022). Launched in October last year (October), it is Lucentis’ first and only FDA-approved biosimilar interchangeable product for any indication whatsoever.

Vabysmo was approved by the FDA in October 2023 to treat macular edema following retinal vein occlusion, according to Genentech’s press release. Vabysmo (faricimab-svoa), which is an inhibitor of the Ang-2 and VEGF-A pathways, showed signs of sustained vision improvement at 24 weeks compared with aflibercept in BALATON and COMINO Phase 3 studies as well as this helps dry up retinal fluid. Overall, the safety profile of Vabysmo was consistent with previous clinical trials, and all participants tolerated it. The most commonly reported (less than 4%) adverse reactions during clinical trials were conjunctival hemorrhages. According to the release, around two million doses have been distributed worldwide for wet AMD and DME treatment across more than 80 countries.

COVID-19 Analysis of Retinal Vein Occlusion Market

The reduction is largely due to the epidemic of COVID-19, which has led to stringent containment initiatives including social distancing, remote jobs, and closing factories and other economic operations, resulting in organisational difficulties. The whole supply chain has been affected, adversely affecting the market.

Takeda’s pharmaceutical drug moves on to be FDA approved, becoming the first ever remedy for a rare hereditary enzyme disorder with complications in blood clotting that end some of them fatally. Congenital thrombotic thrombocytopenic purpura (cTTP), is a disease caused by mutation of ADAMTS13 gene which regulates the process of coagulation. As a result, there is no enzyme produced leading to clots forming in tiny vessels throughout the body. These clots are responsible for recurrent bleeding episodes like strokes and damaging several organs. In the US, this rare illness affects fewer than 1000 individuals according to FDA estimates. Current cTTP treatment involves prophylactic plasma-based therapy with deficient ADAMTS13 replacement aimed at reducing clotting and bleeding risks. Adzynma is a newly engineered version of the key enzyme made by Takeda.

In October 2022, Two Phase III trials of Genentech (Roche)'s Vabysmo hit primary endpoint in macular edema caused by branch and central retinal vein occlusion (BRVO) showing non-inferiority with Regeneron's Eylea. With respect to competing with Regeneron’s Eylea (aflibercept) in the ophthalmology market, data are giving more and more confidence in Vabysmo. Topline data from BALATON and COMINO trials announced showed that patients who received Vabysmo injections every four weeks up to 24 weeks had non-inferior visual acuity gains among those who have macular edema from BRVO or CRVO (central RVO). Compared with persons who get Eylea injections every four weeks.

In June 2022, Lonza and Kodiak Sciences Inc. opened a new custom-built bioconjugation facility within Lonza’s Ibex® Dedicate manufacturing complex in Visp, Switzerland. The facility will enable the commercial manufacture of Kodiak’s leading therapeutic candidate, KSI-301, an antibody biopolymer conjugate for retinal diseases. Once fully operational and subject to approval for commercial use of KSI-301, the facility is expected to have the capacity to produce over 10 million doses of KSI-301 per year. As a result of this collaboration, twelve full-time positions were created at Kodiak Sciences in Visp and an additional seventy at Lonza.

Retinal Vein Occlusion Market Trends

Drivers

Growing Prevalence of Eye Diseases to Fuel Market Growth

The major factors of the retinal vein occlusion market are the rise in prevalence of eye diseases worldwide, increase in geriatric population, increase in understanding of eye disorders, strengthened health care facilities, technological developments, and upcoming novel therapies. The presence of a powerful pipeline and recent drug approvals will fuel the growth of the retinal vein occlusion market. The number of cases of retinal vein occlusion is increasing and there is an increase in the number of molecules under research for treatment. The efficacy of retinal vein occlusion therapy is rising with the presence of a strong pipeline and recent drug approvals. This, in essence, would fuel business growth by embracing retinal vein occlusion therapeutics.

Opportunities

Growing R&D investments to Create Growth Avenues for the Key Players

The global retinal vein occlusion therapeutics industry is positively influenced by developments in drug delivery technology. There are many benefits of innovative drug delivery systems, including decreases in the amount and duration of doses needed to maintain the optimal clinical response, reduced health care costs, and preferential patient compliance. In retinal vein occlusion therapeutics, such benefits would improve end-user demand for innovative drug delivery technologies, driving market development.

Increases in research and investment are expected to build business prospects for the creation of safe and economical therapies by market players.

Restraints

High Treatment-Related Costs Impedes Market Growth

However, the demand is expected to be hampered by the current unmet needs existing in the retinal vein occlusion market for care aimed at restoring vision and at the same time being affordable. There is no question that demand growth is projected to decrease in the forecast timeframe with the introduction of biosimilars into the Retinal vein occlusion market. High treatment-related costs and associated side effects of these therapies are expected to hamper demand development during the forecast period.

The retinal vein occlusion market, by type, has been bifurcated into branch retinal artery occlusion and central retinal vein occlusion.

The retinal vein occlusion industry has been defined as non-ischemic and ischemic based on condition.

Retinal Vein Occlusion Diagnosis Insights

Based on diagnosis, the retinal vein occlusion market has been categorised as optical coherence tomography, fundoscopic examination, fluorescein angiography, and others. During the forecast era, the optical coherence tomography (OCT) segment is projected to rise.

By treatment, has been segmented into antivascular corticosteroid drugs, endothelial growth factor, laser retinal photocoagulation, and others.

The industry has been divided into hospitals and clinics, research & academic centres, and others dependent on end-users. A significant factor in the growth of the hospitals & clinics market is a strong preference for hospitals by the increasing elderly population.

Retinal Vein Occlusion Market Regional Analysis

The geographical overview of the global retinal vein occlusion market has been conducted in four major regions, including the Asia Pacific, North America, Europe, and the rest of the world.

North America leads the Americas with established end-use Sectors

It is estimated that the Americas will have the highest share of the global demand for retinal vein occlusion. North America, primarily because of the growing prevalence of diabetes and the increasing occurrence of diseases such as glaucoma, lymphoma, and multiple myeloma, is expected to lead the market. Due to the rising prevalence of patients, the occurrence of main business players, and the production of surgical outcomes, the region of the Americas also dominates the retinal vein occlusion market. The demand in the area is further bolstered by additional factors, such as the effect of a good economic situation and the focus of academic institutions on upgrading technologies for modern and innovative treatment methods for retinal vein occlusion.

Germany to Lead Europe Market

During the projection period, Europe is projected to account for the second-largest market share. The emergence of a large geriatric population and high healthcare expenditure are the factors responsible for retinal vein occlusion market growth in this region.

APAC to account as Fastest Growing Region

Due to the presence of a significant diabetes patient population, Asia-Pacific is expected to be the fastest-growing region on the global retinal vein occlusion market, the presence of immense market expansion opportunities fuels the growth of the Asia-Pacific retinal vein occlusion market. Due to a rising number of developing nations present in this region, such as nations like China and India, the Asia Pacific region is also the fastest growing retinal vein occlusion market.

MEA Region Driven by Development of the Healthcare Sector

Due to the existence of a well-developed healthcare system, the retinal vein occlusion market in the Middle East & Africa is anticipated to expand. Due to restricted connectivity to medical facilities and the slower development of the healthcare sector, the MEA market is likely to experience gradual growth. However, nations like Kuwait and Qatar are relying more on the healthcare sector and emerging medical facilities, which will improve the region's market.

Competitive Landscape

Key Players focus on Mergers & Acquisitions to Expand their Business Standing

The Retinal Vein Occlusion sector has also become a very dynamic industry and this factor is advantageous to the market analysed as firms gain opportunity to develop their presence. In addition, major market players are concentrating on the extension of their regional presence. The major market players are likely to engage in collaborations, mergers & acquisitions, and product launches to expand their presence in the market and provide effective and reachable patient care.

• Allergan PLC


• Bayer


• Bristol-Myers Squibb


• Ellex Medical Lasers Ltd


• GlaxoSmithKline PLC


• IRIDEX Corporation


• Lumenis


• Novartis AG


• NIDEK CO., LTD


• Regeneron Pharmaceuticals


• Hoffmann-La Roche AG


• Quantel Medical Inc.


• Topcon Medical Systems, Inc.


• ZEISS

Recent Development

December 2020:Arctic Vision, a clinical-stage ophthalmology company headquartered in China with a leading pipeline of breakthrough innovations, announced the approval of the Phase III Investigational New Drug (IND) for the treatment of Uveitic Macular Edema. It was China's first clinical trial for UME therapy and for suprachoroidal space (SCS) injection, which was supposed to include a new treatment choice for UME patients in China.

December 2020:Novartis confirmed promising findings from the first interpretable Phase III results of a clinical trial examining the effectiveness and safety of Beovu. Novartis's Beovu gave Regeneron's an anti-VEGF Eylea, one of the leading therapies to improve diabetic macular edema, close competition.

Retinal Vein Occlusion Market Segmentation

Retinal Vein Occlusion Type Outlook

• Branch Retinal Artery Occlusion


• Central Retinal Vein Occlusion

Retinal Vein Occlusion Condition Outlook

• Non-Ischemic


• Ischemic

Retinal Vein Occlusion Diagnosis Outlook

• Optical Coherence Tomography


• Fundoscopic Examination


• Fluorescein Angiography


• Others

Retinal Vein Occlusion Treatment Outook

• Antivascular Endothelial Growth Factor


• Corticosteroid Drugs


• Laser Retinal Photocoagulation


• Others

Retinal Vein Occlusion End-User Outlook

• Hospitals and Clinics


• Research & Academics Centers


• Others